GlassScriptPhysician profile
Paul Thomas Porter
NPI 1588678155
$7,108.81
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,688 · 2020: $1,238 · 2021: $183.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,954.68 | 2019 | |
| Glaxosmithkline, LLC. | $559.63 | 2020-2021 | |
| Athenex Pharmaceutical Division, LLC | $325.00 | 2020 | |
| Amgen INC. | $319.90 | 2019-2021 | |
| Janssen Biotech, INC. | $165.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $138.41 | 2019-2020 | |
| Clovis Oncology, INC. | $93.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $74.69 | 2019-2021 | |
| Pfizer INC. | $70.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.26 | 2019-2021 | |
| Gilead Sciences, INC. | $54.43 | 2019 | |
| Lilly USA, LLC | $37.90 | 2019 | |
| Dova Pharmaceuticals | $34.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $30.88 | 2019-2020 | |
| Seagen INC. | $30.60 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.99 | 2019 | |
| Genzyme Corporation | $23.06 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.97 | 2020 | |
| Fortovia Therapeutics, INC. | $19.88 | 2019 | |
| Exelixis INC. | $17.66 | 2019 | |
| Beigene USA, INC. | $15.64 | 2020 | |
| Kite Pharma, INC. | $15.54 | 2020 | |
| Medtronic USA, INC. | $13.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.